Articles On Starpharma Holdings (ASX:SPL)

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

In this interview Dale Gillham and small cap company director Rod North discuss what to look for in microcap stocks and what place they should have in an investor’s portfolio. They discuss success stories, risk vs reward, and, the challe...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Overview of Market Movements  As of 8:30 am AEST, ASX 200 futures have shown a modest increase of 4 points, representing a 0.05% rise. This slight upward movement reflects a cautious tone in the market as global investors digest the latest...

ASX healthcare shares Starpharma Holdings Ltd (ASX: SPL) and Mesoblast Ltd (ASX: MSB) are outgunning their peers today after the companies released positive news for shareholders. The Starpharma share price is up 3.41% to 9.1 cents afte...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

With Starpharma (ASX:SPL) shares having lost losing three-quarters of their value over the previous year when new CEO Cheryl Maley reported for duty on January 8 this year, the former big drug company exec knew that maintaining the status q...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Insider buying often signals confidence in a company's future, and a few cheap ASX shares have caught investor attention recently due to notable insider activity. This kind of buying activity can be a strong indicator of growth potentia...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Starpharma (ASX: SPL) has announced positive anti-tumour efficacy results from a Phase 2 clinical trial of its lead candidate DEP irinotecan in heavily pre-treated patients with a range of difficult-to-treat advanced and metastatic cancers....

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Several ASX companies are repurposing or resurrecting abandoned or under utilised drugs  Paradigm Biopharmaceuticals identified the potential of FDA-approved PPS that has a long track record of treating inflammation Starpharma has develope...

Australian company Starpharma (ASX:SPL) has announced a strategic partnership with Medicxi to co-found a new UK-based company called Petalion Therapeutics.

The ASX200 closed up slightly by +0.1% on Monday as gains in tech and gold stocks were offset by losses in the energy sector.  Energy stocks struggled as crude prices fell more than US$1 a barrel in Asian hours today after Israel confirmed...

Australian biotech Starpharma Holdings (ASX: SPL) has entered into a strategic partnership with UK life sciences investment firm Medicxi to establish a UK-based company known as Petalion Therapeutics. Petalion will initially focus on develo...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Starpharma suffers setback after US FDA appeal rejected LTR Pharma to commence study on erectile dysfunction nasal spray, SPONTAN   Starpharma suffers FDA setback Starpharma (ASX:SPL) fell -10% this morning after announcing a negative out...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

There have been some big movers in the healthcare sector on Wednesday. Here's why these ASX healthcare shares are up over 10% today: Mayne Pharma Group Ltd (ASX: MYX) The Mayne Pharma share price is up over 13% to $3.12. Investors have be...

Starpharma (ASX:SPL) has announced the presentation of data that it says demonstrate the benefits of combining its DEP irinotecan with other important classes of anti-cancer therapies, including immuno-oncology (IO) agents, in model...

Dimerix’s drug granted QYTOVRA as brand name by US FDA Starpharma completes recruitment for VIRALEZE study in UK Invion adds South Korea to list of exclusive territories for Photosoft    FDA says QYTOVRA can be used as DMX-200 brand name...

  Dr Jackie Fairley – CEO – Starpharma Holdings (ASX:SPL) is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

After a stronger-than-expected US inflation figure for August, the Australian August job report blew expectations out of the water, with 64,900 jobs created in the month, well above the 23,000 anticipated by economists. The unemployment rat...

A tech slide dragged the ASX indices lower on Wednesday, ahead of the US inflation data coming in overnight. Consensus expectations were for the US headline consumer price index (CPI) to show core inflation at 3.6% for the year to August, u...

Australian company Starpharma (ASX:SPL) has announced it will present positive interim data from the trial of its DEP irinotecan at a key international oncology conference in October in the US.

ASX 200 falls sharply from the open, tracking Wall St sell off ahead of US CPI read tonight Most sectors decline led by Tech and Industrials Tempus Resources jumps 50%, cops a speeding ticket   Australian shares stepped off the into th...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

It has been a disappointing day for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade, the benchmark index is down 0.8% to 7,147 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they are...

Starpharm jumps after disclosing interim Phase 1/2 results Chimeric Therapeutics to commence Phase 1b clinical trial Island Pharma gets key patent grant in the US   Starpharma jumps after positive Phase 1/2 results Starpharma (ASX:SPL) ju...

The Starpharma Holdings Ltd (ASX: SPL) share price came rocketing out of the gates this morning. At one stage, the dendrimer products developer's shares were up as much as 58% to 20.5 cents. Starpharma's shares have pulled back a touch sin...

Stockhead’s Top 10 at shortly-before-11-ish, published surprisingly close to on time, considering I was still shaking the tiles off the roof with my snoring when the market doors opened today. It highlights the best (and sometimes worst) pe...

The S&P ASX 200 was down 0.73% in August with mid caps and small caps down 1.3% for the month Eight of 11 sectors down in August with consumer discretionary leading winners and utilities the laggards Tech stock 4DS Memory rises more th...

These four ASX healthcare shares are bucking the trend today with strong share price gains following the release of their latest financial reports. As earnings season continues, the S&P/ASX 200 Health Care Index (ASX: XHJ) is down 0.0...

Local shares to open lower on Monday as US Big Tech retreated Bill Gross says Treasuries are overvalued City Index provides three most common type of scams   The ASX is set to open lower by -0.35% on Monday as Wall Street ended mixed in a...

The ASX couldn’t make up its mind, a bit like economists looking ahead to the RBA decision tomorrow. Health Care and Industrials Stocks had a day to savour, while Staples and IT largely did not. Some standout small caps: TALi Digital, Ecof...

The S&P/ASX 200 Index (ASX: XJO) has started the week in a subdued fashion. In afternoon trade, the benchmark index is down 0.2% to 7,388.3 points. Four ASX shares that are falling more than most today are listed below. Here’s why...

The Starpharma Holdings Ltd (ASX: SPL) share price is ending the month in disastrous fashion. In morning trade, the ASX All Ords biotechnology share is down 34% to a 52-week low of 21.5 cents. Why is this ASX All Ords share being sold off?...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) looks set to end its losing streak. At the time of writing, the benchmark index is up 0.5% to 7,116 points. Four ASX shares that have failed to follow the market higher today are li...

Starpharma (ASX:SPL) has announced the recent presentation of AZD0466 clinical data by AstraZeneca at the European Hematology Association 2023 Hybrid Congress.

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

Anteris’ study is progressing well at the one year and 30-day time points Imugene’s Phase 1 trial has progressed to the next cohort level Nyrada has a new lead drug   Regenerative medicine biotech Anteris Technologies (ASX:AVR) has just p...

Starpharma’s (ASX:SPL) Chief Executive Officer, Dr Jackie Fairely, resigns after 16 years in the role During her tenure, Dr Fairley “transformed” Starpharma from a startup to a “mature organisation” with multiple commercial partnership...

Starpharma (ASX:SPL) has announced that it has achieved regulatory approval for its antiviral nasal spray product, Viraleze, in Malaysia.

OncoSil gets Ethics committee approval Starpharma’s  nasal spray VIRALEZE granted approval in Malaysia Botanix Pharmaceuticals strikes deal in Korea   Medical device OncoSil Medical (ASX:OSL) rose 8% this morning after the Ethics committe...

Biotech Starpharma has received regulatory approval for its Viraleze product to be used in Malaysia, adding the product to a wider market base that now spans 35 countries as it looks into further COVID-19 studies in the UK. The post Starpha...

Starpharma (SPL) secures regulatory approval for its VIRALEZE antiviral nasal spray in Malaysia The registration of VIRALEZE in Malaysia will allow Starpharma and its commercial partners to market and sell the product throughout the coun...